### **ABOUT THE SURVEY**

42 CFR 438.3(s)(4) and (5) require that each Medicaid managed care organization (MCO) must operate a drug utilization review (DUR) program that complies with the requirements described in Section 1927 (g) of the Social Security Act (the Act) and submit an annual report on the operation of its DUR program activities. Such reports are to include: descriptions of the nature and scope of the prospective and retrospective DUR programs; a summary of the interventions used in retrospective DUR and an assessment of the education program; a description of DUR Board activities; and an assessment of the DUR program's impact on quality of care.

Note: Covered Outpatient Drugs (COD) are referenced throughout this survey and refers to participating labelers in the Medicaid Drug Rebate Program (MDRP).

This report covers the period October 1, 2019 to September 30, 2020. Answering the attached questions and returning the requested materials as attachments to the report will constitute compliance with the above-mentioned statutory and regulatory requirements.

If you have any questions regarding the DUR Annual Report, please contact your state's Medicaid Pharmacy Program.

**IMPORTANT NOTE:** Adobe Acrobat Reader must be used to edit the survey. The MCO survey cannot be edited within a browser window.

Pursuant to 42 C.F.R. Subpart A, Section § 438.3 (s), Medicaid managed care programs must submit to CMS an annual report on the operation of its DUR program activities for that Federal Fiscal Year (FFY). Beginning with FFY 2020 surveys, individual managed care plan's survey results will be published online and will be publically available similar to the FFS surveys which have been published on *Medicaid.gov* since 2010. Please confirm and acknowledge there is no proprietary or confidential information submitted in this report by checking the box below:

• I confirm I am aware this survey will be posted online. Confidential and proprietary information has been removed from this survey.

#### PRA DISCLOSURE STATEMENT (CMS-R-153)

This mandatory information collection (section 4401 of the Omnibus Budget Reconciliation Act of 1990 and section 1927(g) of the Social Security Act) is necessary to establish patient profiles in pharmacies, identify problems in prescribing and/or dispensing, determine each program's ability to meet minimum standards required for Federal financial participation, and ensure quality pharmaceutical care for Medicaid patients. State Medicaid agencies that have prescription drug programs are required to perform prospective and retrospective DUR in order to identify aberrations in prescribing, dispensing and/or patient behavior. Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The control number for this information collection request is 0938-0659 (Expires: 11/30/2022). Public burden for all of the collection of information requirements under this control number is estimated at 64 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.

Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

# I. <u>DEMOGRAPHIC INFORMATION</u>

State Abbreviation: \_\_\_\_\_

MCO Name:

Please Note: Name above must match name entered in Medicaid Drug Program (MDP) DUR system

Program Type (See Appendix A):

If "Other", please specify.

# **Medicaid MCO Information**

Identify the MCO person responsible for DUR Annual Report Preparation.

First Name:

Last Name:

Email Address:

Area Code/Phone Number:

On average, how many Medicaid beneficiaries are enrolled monthly in your MCO for this Federal Fiscal Year?

\_\_\_\_\_ Beneficiaries

# II. PROSPECTIVE DUR (ProDUR)

1. Indicate the type of your pharmacy point of service (POS) vendor and identify it by name.

O State-operated

O Contractor, please identify by name.

O Other organization, please identify by name.

- 2. Identify ProDUR table driven criteria source. This would be initial ratings such as drug to drug interactions, dose limits based on age and pregnancy severity.
  - O First Data Bank
  - O Medi-Span
  - O MICROMEDEX
  - O Other, please specify.
- 3. When the pharmacist receives a ProDUR alert message that requires a pharmacist's review, does your system allow the pharmacist to override the alert using the "National Council for Prescription Drug Program (NCPDP) drug use evaluation codes" (reason for service, professional service and resolution)?

O YesO Varies by Alert TypeO No

If "Yes" or "Varies by Alert Type", check **all** that apply.

- O Alerts can be overridden ahead of time
- O Alerts can be overridden with standard professional codes
- O Alerts need prior authorization to be overridden.
- O Other, please explain.

4. Do you receive periodic reports providing individual pharmacy provider DUR alert override activity in summary and/or in detail?

O Yes

a. How often? O Monthly

- O Quarterly
- O Annually
- O Ad hoc (on request)
- O Other, please explain.

- b. If you receive reports, do you follow up with those providers who routinely override with interventions?
  - O Yes

By what method do you follow up?

- O Contact Pharmacy
- O Refer to Program Integrity (PI) for Review
- O Other, please explain.

O No

O No, please explain.

- 5. Early Refill
  - a. At what percent threshold do you set your system to edit?

i. Non-controlled drugs:

\_\_\_\_\_%

ii. Schedule II controlled drugs:

\_\_\_\_\_%

iii. Schedule III through V controlled drugs:

\_\_\_\_\_%

b. For non-controlled drugs:

When an early refill message occurs, does your MCO require prior authorization (PA)?

- O Yes
- O No
- O Dependent on the medication or situation

If "Yes" or "Dependent on medication or situation", who obtains authorization?

- O Pharmacist
- O Prescriber
- O Pharmacist or Prescriber

If "No", can the pharmacist override at the point of service?

- O Yes
- O No
- c. For controlled drugs:

When an early refill message occurs, does your MCO require PA?

- O Yes
- O No

If "Yes", who obtains authorization?

- O Pharmacist
- O Prescriber
- O Pharmacist or Prescriber

If "No", can the pharmacist override at the point of service?

- O Yes O No
- 6. When the pharmacist receives an early refill DUR alert message that requires the pharmacist's review, does your policy allow the pharmacist to override for situations such as:
  - a. Lost/stolen Rx
    - O Yes
    - O No
    - O Overrides are only allowed by a pharmacist through a PA
  - b. Vacation
    - O Yes
    - O No
    - O Overrides are only allowed by a pharmacist through a PA
  - c. Other, please explain.

7. Does your system have an accumulation edit to prevent patients from continuously filling prescriptions early?

O Yes O No

If "Yes", please explain your edits.

If "No", do you plan to implement this edit?

O Yes

- O No
- 8. Does the MCO have any policy prohibiting the auto-refill process that occurs at the POS (i.e. must obtain beneficiary's consent prior to enrolling in the auto-refill program)?

O Yes O No

9. For drugs not on your MCO's Preferred Drug List (PDL), does your MCO have a documented process (i.e. PA) in place, so that the Medicaid beneficiary or the Medicaid beneficiary's prescriber may access any covered outpatient drug when medically necessary?

O Yes

Please check **all** that apply.

- O Automatic PA based on diagnosis codes or systematic review
- O Trial and failure of first or second line therapies
- O Pharmacist or technician reviews
- O Direct involvement with Pharmacy and/or Medical Director
- O Other, please explain.

O No, please explain.

a. How does your MCO ensure PA criteria is no more restrictive than the FFS criteria and review? Please describe the process.

-		
b.	-	program provide for the dispensing of at least a 72-hour supply of an emergency situation?
	O Yes.	, please check <b>all</b> that apply.
	0	Real time automated process
	0	Retrospective prior authorization
	0	Other process, please explain.
	•	
	O No, pl	ease explain.
	-	ested data in each category in <b>Table 1</b> : <b>Top Drug Claims Data</b> <b>DUR Board</b> below.
Column	-	0 PA Requests by Drug Name, report at generic ingredient level ( <i>See dix B for the list of Drug Names</i> )
	1 2 – Top 1	0 PA Requests by Drug Class (See Appendix C for Drug Class names)
Column		Claim Denial Reasons (i.e. Quantity Limits (QL), Early Refill (ER),
		herapeutic Duplications (TD), and Age Edits (AE) (See Appendix D e list of Denial Reasons)
Column	4 – Top 1	0 Drug Names by Amount Paid, report at generic ingredient level (See dix B for the list of Drug Names)
Column		Data in column 4, determine the Percentage of Total Drug Spend

Column 6 – Top 10 Drug Names by Claim Count, report at generic ingredient level (See Appendix B for the list of Drug Names)

Column 7 – From Data in Column 6, determine the Percentage of Total Claim

# Table 1: Top Drug Claims Data Reviewed by the DUR Board

Column 1 Top 10 Prior Authorization (PA) Requests by Drug Name, report at generic ingredient level	Column 2 Top 10 Prior Authorization (PA) Requests by Drug Class	Column 3 Top 5 Claim Denial Reasons Other Than Eligibility (i.e. Quantity Limits, Early Refill, PA, Therapeutic Duplications, Age Edits)	Column 4 Top 10 Drug Names by Amount Paid, report at generic ingredient level	Column 5 % of Total Spent for Drugs by Amount Paid (From data in Column 4, Determine the % of total drug spend)	Column 6 Top 10 Drug Names by Claim Count, report at generic ingredient level	Column 7 Drugs by Claim Count % of Total Claims (From data in Column 6, Determine the % of total claims)
				%		%
				%		%
				%		%
				%		%
				%		%
				%		%
				%		%
				%		%
				%		%

# III. <u>RETROSPECTIVE DUR (RetroDUR)</u>

- 1. Please indicate how your MCO operates and oversees RetroDUR reviews?
  - O State-operated interventions
  - O Managed Care executes its own RetroDUR activities
  - O Pharmacy Benefit Manager (PBM) performs RetroDUR activities
  - O Combination of MCO RetroDUR interventions and state interventions are performed
  - O Other, please explain.

- 2. Indicate the type of vendor that performed your RetroDUR activities during the time period covered by this report.
  - O Company
  - O Academic Institution
  - O Other Institution
    - a. Identify, by name, your RetroDUR vendor.
    - b. Is the RetroDUR vendor the developer/supplier of your RetroDUR criteria?
      - i. Yes, please explain.

ii. No, please explain.

- c. Do you customize your RetroDUR vender criteria?
  - O Yes
  - O No
  - O Ad hoc based on state-specific needs
- 3. Who reviews and approves the RetroDUR criteria?
  - O State DUR Board
  - O MCO DUR Board
  - $O\ \ PBM$  performs RetroDUR and has a RetroDUR Board
  - O PBM Pharmacy and Therapeutics (P&T) Board also functions as a DUR Board
  - O State Pharmacy Director
  - O Other, please explain.

- 4. How often does your MCO perform retrospective practitioner based education?
  - O Monthly
  - O Bi-monthly
  - O Quarterly
  - O Other, please specify: \_\_\_\_\_
    - a. How often do you perform retrospective reviews that involves communication of client specific information to healthcare practitioner (through messaging, fax, or mail)? Check **all** that apply.
      - O Monthly
      - O Bi-monthly
      - O Quarterly

O Other, please specify: \_\_\_\_\_

- b. What is the preferred mode of communication when performing RetroDUR initiatives (check all that apply)?
  - O Mailed letters
  - O Provider phone calls
  - O Near real time fax
  - O Near real time messaging
  - O Other new technologies such as apps or Quick Response (QR) codes
  - O Focused workshops, case management or WebEx training
  - O Newsletters or other non-direct provider communications
  - O Other, please specify:

### 5. Summary 1: RetroDUR Educational Outreach

Summary 1: RetroDUR Educational Outreach is a year-end summary report on RetroDUR screening and educational interventions. The summary should be limited to the most prominent problems with the largest number of exceptions. The results of retrospective DUR screening and interventions should be included and detailed below.

# IV. DUR BOARD ACTIVITY

1. Does your MCO utilize the same DUR Board as the state Fee-For-Service (FFS) Medicaid Program or does your MCO have its own DUR Board?

O Same DUR Board as FFS agency

O MCO has its own DUR BoardO Other, please explain.

# 2. Summary 2: DUR Board Activities Report

Summary 2: DUR Board Activities Report should be a brief descriptive report on DUR activities during the fiscal year reported. Please provide a detailed summary below:

- Indicate the number of DUR Board meetings held.
- List additions/deletions to DUR Board approved criteria:
  - For ProDUR, list problem type/drug combinations added or deleted.
  - For RetroDUR, list therapeutic categories added or deleted.
- Describe Board policies that establish whether and how results of ProDUR screening are used to adjust RetroDUR screens.
- Describe policies that establish whether and how results of RetroDUR screening are used to adjust ProDUR screens.
- Describe DUR Board involvement in the DUR education program (i.e. newsletters, continuing education, etc.).
- Describe policies adopted to determine mix of patient or provider specific intervention types (i.e. letters, face-to-face visits, increased monitoring).

- 2. Does your MCO have a Medication Therapy Management (MTM) Program?
  - O Yes

O No

### V. PHYSICIAN ADMINISTERED DRUGS (PAD)

The Deficit Reduction Act requires collection of national drug code (NDC) numbers for covered outpatient physician administered drugs. These drugs are paid through the physician and hospital programs. Has your pharmacy system been designed to incorporate this data into your DUR criteria for:

1. ProDUR?



If "No", do you have a plan to include this information in your DUR criteria in the future?

O Yes O No

- 2. RetroDUR?
  - O Yes
  - O No

If "No", do you have a plan to include this information in your DUR criteria in the future?

O Yes

O No

### VI. GENERIC POLICY AND UTILIZATION DATA

## 1. Summary 3: Generic Drug Substitution Policies

Summary 3: Generic Drug Substitution Policies summarizes should summarize factors that could affect your generic utilization percentage. In describing these factors, please explain any formulary management or cost containment measures, PDL policies, educational initiatives, technology or promotional factors, or other state specific factors that affects your generic utilization rate.

2.	Medically I	to the requirement that the prescriber write in his own handwriting "Brand Necessary" for a brand name drug to be dispensed in lieu of the generic does your MCO have a more restrictive requirement?
	O Yes O No	
	If "Yes	", check <b>all</b> that apply.
	C	D Require that a MedWatch Form be submitted
		Require the medical reason(s) for override accompany the prescription(s)
		<ul><li>PA is required</li><li>Other, please explain.</li></ul>
		o thei, please explain.

### Table 2: Generic Drug Utilization

#### **Computation Instructions**

#### KEY

**Single Source (S)** – Drugs having an FDA New Drug Application (NDA), and there are no generic alternatives available on the market.

**Non-Innovator Multiple-Source** (N) – Drugs that have an FDA Abbreviated New Drug Application (ANDA), and generic alternatives exist on the market

**Innovator Multiple-Source (I)** – Drugs which have an NDA and no longer have patent exclusivity.

1. **Generic Utilization Percentage:** To determine the generic utilization percentage of all covered outpatient drugs paid during this reporting period, use the following formula:

 $N \div (S + N + I) \times 100$  = Generic Utilization Percentage

2. Generic Expenditures Percentage of Total Drug Expenditures: To determine the generic expenditure percentage (rounded to the nearest \$1000) for all covered outpatient drugs for this reporting period use the following formula:

 $N \div (S + N + I) \times 100 = Generic Expenditure Percentage$ 

CMS has developed an extract file from the Medicaid Drug Rebate Program Drug Product Data File identifying each NDC along with sourcing status of each drug: S, N, or I, which can be found at Medicaid.gov (Click on the link "an NDC and Drug Category file [ZIP]," then open the Medicaid Drug Product File 4th Qtr. 2020 Excel file). Please provide the following utilization data for this DUR reporting period for all covered outpatient drugs paid. Exclude Third Party Liability (TPL).

	Single Source (S) Drugs	Non-Innovator (N) Drugs	Innovator Multi Source(I) Drugs
Total Number of Claims			
Total Reimbursement Amount Less Co-Pay			

3. Indicate the generic utilization percentage for all CODs paid during this reporting period, using the computation instructions in **Table 2: Generic Utilization Data**.

Number of Generic Claims	
Total Number of Claims	
Generic Utilization Percentage	%

- 4. How many multi source drugs have the innovator as the State's preferred drug product based on net pricing?
- 5. Indicate the percentage dollars paid for generic covered outpatient drugs in relation to all COD claims paid during this reporting period using the computation instructions in

### Table 2: Generic Utilization Data.

Generic Dollars:	\$ 
Total Dollars:	\$ 
Generic Expenditure Percentage:	 %

6. Does your MCO have any policies related to Biosimilars? Please explain.

# VII. FRAUD, WASTE, AND ABUSE DETECTION (FWA)

### A. LOCK-IN or PATIENT REVIEW AND RESTRICTION PROGRAMS

- 1. Do you have a documented process in place that identifies potential FWA of controlled drugs by **beneficiaries**?
  - O Yes

O No

If "Yes," what actions does this process initiate? Check all that apply.

- O Deny claims and require PA
- O Refer to Lock-In Program
- O Refer to Program Integrity Unit (PIU)/Surveillance Utilization Review (SUR) Unit
- O Refer to Office of Inspector General (OIG)
- O Other, please explain.

2. Do you have a Lock-In program for beneficiaries with potential FWA of controlled substances?

O Yes O No

If "No", skip to question 3.

If "Yes", please continue.

a. What criteria does your MCO use to identify candidates for Lock-In? Check **all** that apply.

- O Number of controlled substances (CS)
- O Different prescribers of CS
- O Multiple pharmacies
- O Number days' supply of CS
- O Exclusivity of short acting opioids
- O Multiple ER visits
- O PDMP data
- O Same FFS state criteria is applied
- O Other, please explain.

- b. Do you have the capability to restrict the beneficiary to:
  - i. Prescriber only
    - O Yes O No
  - ii. Pharmacy only
    - O Yes O No
  - iii. Prescriber and pharmacy
    - O Yes O No
- c. On average, what percentage of your Medicaid MCO population is in Lock-In status annually?

\_\_\_\_%

3. Do you have a documented process in place that identifies possible FWA of controlled drugs by **prescribers**?

# O Yes

What actions does this process initiate? Check all that apply.

- O Deny claims written by this prescriber
- O Refer to Program Integrity Unit
- O Refer to the appropriate Medical Board
- O Other, please explain.

O No, please explain.

4. Do you have a documented process in place that identifies potential FWA of controlled drugs by **pharmacy providers**?

O Yes

What actions does this process initiate? Check all that apply.

- O Deny claims
- O Refer to Program Integrity Unit
- O Refer to the Board of Pharmacy
- O Other, please explain.

O No, please explain.

_	
_	
	ou have a documented process in place that identifies and/or prevents potentia A of non-controlled drugs by <b>beneficiaries</b> ?
0	Yes
]	Please explain your program for FWA of non-controlled substances.
<u>.</u>	
-	
0	No, please explain.

# **B. PRESCRIPTION DRUG MONITORING PROGRAM(PDMP)**

Note: Section 5042 of the SUPPORT for Patients and Communities Act requires states to report metrics in reference to their state's PDMP. CMS has included questions to reference these metrics to help establish processes to be in compliance with provisions outlined in Section 5042 and CMS reporting, beginning in FFY 2023. Please complete applicable questions below in this section of the survey.

1. Does your state have a PDMP?

O YesO No, please explain and go to Section C.

If "Y	es", please continue.
a.	Does your MCO have the ability to query the state's PDMP database?
	O Yes, receive PDMP data
	O Daily
	O Weekly
	O Monthly
	O Other
	O Yes, have direct access to the database
	O Can query by client
	O Can query by prescriber
	O Can query by dispensing entity
	O No
	If "Yes", please continue.
	i. Please explain how your program applies this information to control FWA of controlled substances.

- ii. Does your MCO have access to border states' PDMP information?
  - O Yes
  - O No
- iii. Are there barriers that hinder your MCO from fully accessing the

PDMP that prevent the program from being utilized the way it was intended to be to curb FWA?

0	Yes,	please	explain	the	barriers	that	exist.
---	------	--------	---------	-----	----------	------	--------

- O No
- iv. Do you also have PDMP data integrated into your POS edits?
  - O Yes O No
- 2. Do you or the professional board require prescribers (in your provider agreement) to access the PDMP patient history before prescribing controlled substances?
  - O Yes
  - O No

If "Yes", please continue.

a. Are there protocols involved in checking the PDMP?

O Yes, please explain.

O No

b. Are providers required to have protocols for responses to information from the PDMP that is contradictory to the direction that the practitioner expects from the client?

	0 y 0 y	
c.	the pr	rovider is not able to conduct PDMP check, do you require rescriber to document a good faith effort, including the ns why the provider was not able to conduct the check?
	0	Yes
	0	No, please explain.
		If "Yes", do you require the provider to submit, upon request, documentation to the MCO?
		O Yes
		O No, please explain.

3. Does your MCO require pharmacists to check the PDMP prior to dispensing?

O Yes O No, please explain.

If "Yes", are there protocols involved in checking the PDMP?

O Yes, please explain.

O No
------

- 4. In the State's PDMP system, which of the following pieces of information with respect to a beneficiary, is available to prescribers as close to real-time as possible? Check **all** that apply.
  - O PDMP drug history
  - O The number and type of controlled substances prescribed to and dispensed to the beneficiary during at least the most recent 12-month period.
  - O The name, location, and contact information, or other identifying number, such as a national provider identifier, for previous beneficiary fills
  - O Other, please explain.

- Please specify below the following information for the 12-month reporting period for this survey. Note: Mandatory reporting will be required in FFY2023 under Section 1927(g)(3)(D) of the Act.
  - a. The percentage of covered providers who checked the prescription drug history of a beneficiary through a PDMP before prescribing a controlled substance to such an individual:

\_\_\_\_%.

- Average daily MME prescribed for controlled substances per covered individuals:
   \_\_\_\_\_MMEs
- c. Average daily MME prescribed for controlled substances per covered individuals who are receiving opioids.

\_\_\_\_\_MMEs

d. Please complete Tables 3, 4, 5 and 6 below. Specify the controlled substances prescribed based on claim count (by generic ingredient(s)) and within each population during this FFY reporting period.

Population	Top 3 Opioid Controlled Substances Prescribed Based On Claim Count (Generic Ingredient) within Each Population	Total Number of Beneficiaries Within Each Population	Number of Beneficiaries in Each Population/ Month Receiving Controlled Substances	Percentage of Population Receiving Controlled Substances (Auto Calculate)
0-18 yrs				
19-29 yrs				
30-39 yrs				
40-49 yrs				
50-59 yrs				
60-69 yrs				
70-79 yrs				
80+ yrs				
Individuals with Disabilities Utilizing State Eligibility Categories				

# Table 4: Top Sedative/Benzodiazepines Controlled Substances by Population

• When listing the controlled substances in different drug categories, for the purpose of Table 4 below, please consider long and short acting benzodiazepines to be in the same category.

Population	Top 3 Sedative/ Benzodiazepine Controlled Substances Prescribed Based On Claim Count (Generic Ingredient) within Each Population	Total Number of Beneficiaries within Each Population	Number of Beneficiaries in Each Population/ Month Receiving Sedative/ Benzodiazepine Controlled Substances	Percentage of Population Receiving Sedative/ Benzodiazepine Controlled Substances (Auto Calculate)
0-18 yrs				
19-29 yrs				
30-39 yrs				
40-49 yrs				
50-59 yrs				
60-69 yrs				
70-79 yrs				
80+ yrs				
Individuals with Disabilities Utilizing State Eligibility Categories				

### Table 5: Top Stimulant/ADHD Controlled Substances by Population

• When listing the controlled substances in different drug categories, for the purpose of Table 5 below, please consider long and short acting ADHD medications to be in the same category.

Population	Top 3 Stimulant/ADHD Controlled Substances Prescribed Based On Claim Count (Generic Ingredient) within Each Population	Total Number of Beneficiaries within Each Population	Number of Beneficiaries In Each Population/ Month Receiving Stimulant/ADHD Controlled Substances	Percentage of Population Receiving Stimulant/ADHD Controlled Prescriptions (Auto Calculate)
0-18 yrs				
19-29 yrs				
30-39 yrs				
40-49 yrs				
50-59 yrs				
60-69 yrs				
70-79 yrs				
80+ yrs				
Individuals with Disabilities				
Utilizing State Eligibility Categories				

# Table 6: Populations on 2 or more Controlled Substances in Different Drug Categories

• When listing the controlled substances in different drug categories, for the purpose of Table 6 below, please consider long and short acting opioids to be in the same category. Please follow this approach for long and short acting ADHD medications and benzodiazepines in this table as well.

Population	Total Number of Beneficiaries within Each Population	Number of Beneficiaries in Each Population/ Month Receiving 2 or more Controlled Substances in Different Drug Categories	Number of Beneficiaries in Each Population/ Month Receiving 3 or more Controlled Substances in Different Drug Categories	Percentage Of Population Receiving 2 or more Controlled Substances (Auto Calculate)
0-18 yrs				
19-29 yrs				
30-39 yrs				
40-49 yrs				
50-59 yrs				
60-69 yrs				
70-79 yrs				
80+ yrs				
Individuals with Disabilities Utilizing State Eligibility Categories				

i. If there is additional information you want to provide for the previous 12-month reporting period, please explain below.

ii. If any of the information requested is not being reported above, please explain below.

6. In this reporting period, have there been any data or privacy breaches of the PDMP or PDMP data?

O Yes O No

If "Yes", please summarize the breach, the number of individuals impacted, a description of the steps the State has taken to address each such breach, and if law enforcement or the affected individuals were notified of the breach.

# C. OPIOIDS

- 1. Do you currently have a POS edit in place to limit the quantity dispensed of an initial opioid prescription?
  - O Yes, for all opioids
  - O Yes, for some opioids
  - O No for all opioids

Please explain responses above.

If "No", skip to question 1b.
a. Is there more than one quantity limit for various opioids? Additionally, please explain ramifications when addressing COVID-19 if applicable.
O Yes, please explain.
O No
b. What is the maximum number of days allowed for an initial opioid prescription for an opioid naïve patient?
# of days
c. Does this days' supply limit apply to <b>all</b> opioid prescriptions?
<ul> <li>O Yes, for all opioids</li> <li>O Yes, some opioids</li> <li>O No</li> </ul>
Please explain response above.

2. For subsequent prescriptions, do you have POS edits in place to limit the quantity dispensed of short-acting (SA) opioids?

O Yes

What is your maximum days' supply per prescription limitation?

- O 30-day supply
- O 34-day supply
- O 90-day supply
- O Other, please explain.

O No, please explain.

3. Do you currently have POS edits in place to limit the quantity dispensed of long-acting (LA) opioids?

O Yes

What is your maximum days' supply per prescription limitation?

- O 30-day supply
- O 34-day supply
- O 90-day supply
- O Other, please explain.

O No, please explain.

- 4. Do you have measures other than restricted quantities and days' supply in place to either monitor or manage the prescribing of opioids?
  - O Yes

O No

If "Yes", please check **all** that apply.

- O Pharmacist override
- O Deny claim and require PA
- O Intervention letters
- O Morphine Milligram Equivalent (MME) daily dose program
- O Step therapy or Clinical criteria
- O Requirement that patient has a pain management contract or Patient-Provider agreement
- O Requirement that prescriber has an opioid treatment plan for patients
- O Require documentation of urine drug screening results
- O Require diagnosis
- O Require PDMP checks
- O Workgroups to address opioids
- O Other, please specify.

Please provide details on these opioid prescribing controls in place.

		If "No", please explain what you do in lieu of the above or why you do not have measures in place to either manage or monitor the prescribing of opioids.			
5.	Do you have POS edits to monitor duplicate therapy of opioid prescriptions? This excludes regimens that include a single extended release product and a breakthrough short acting agent.				
	0 0	Yes No			
		Please explain response above.			
6.		you have POS edits and automated retrospective claim reviews to monitor duplicate apy of opioid prescriptions dispensed?			

- O Yes, POS edits
- O Yes, automated retrospective claim reviews
- O Yes, both POS edits and automated retrospective claim reviews
- O No

If any response is "Yes", please explain scope and nature.

		If "No", please explain.
7.		you have POS edits and automated retrospective claim reviews to monitor early ills of opioid prescriptions dispensed?
	0 0	Yes, POS edits Yes, automated retrospective claim reviews Yes, both POS edits and automated retrospective claim reviews No
		If any response is "Yes", please explain scope and nature of reviews and edits.
		If "No", please explain.

8. Do you have a comprehensive automated retrospective claims review process to monitor opioid prescriptions exceeding state limitations?

O Yes, please explain in detail the scope and nature of these retrospective reviews.

С	No, please explain.
	Do you currently have POS edits in place or a retrospective claims review to monitor opioids and benzodiazepines being used concurrently?
	<ul> <li>Yes, POS edits</li> <li>Yes, automated retrospective claim reviews</li> <li>Yes, both POS edits and automated retrospective claim reviews</li> </ul>
	Please explain the above response and detail the scope and nature of these review and edits. Additionally, please explain any potential titration processes utilized fo those patients chronically on benzodiazepines and how the state justifies pain medications, i.e. Oxycodone/APAP, for breakthrough pain without jeopardizing patient care (i.e. quantity limits/practitioner education titration programs).
(	O No, please explain.

10. Do you currently have POS edits in place or an automated retrospective claims review to monitor opioids and sedatives being used concurrently?

O Yes, POS edits

O Yes, automated retrospective claim reviews

O Yes, both POS edits and automated retrospective claim reviews

Please explain above response and detail the scope and nature of reviews and/or edits.

O No, please explain.

- 11. Do you currently have POS edits in place or an automated retrospective claims review to monitor opioids and antipsychotics being used concurrently?
  - O Yes, POS edits
  - O Yes, automated retrospective claim reviews
  - O Yes, both POS edits and automated retrospective claim reviews

Please explain above response and detail the scope and nature of reviews and/or edits.

O No, please explain.

- 12. Do you have POS safety edits or perform RetroDUR activity and/or provider education in regard to beneficiaries with a diagnosis history of opioid use disorder (OUD) or opioid poisoning diagnosis?
  - O Yes, POS edits
  - O Yes, RetroDUR activity and/or provider education
  - O Yes, both POS edits and RetroDUR activity and/or provider education
  - O No

If "Yes, RetroDUR activity and/or provider education," please continue.

- a. Please indicate how often.
  - O Monthly
  - O Quarterly
  - O Semi-Annually
  - O Annually
  - $O \quad {\rm Ad \ hoc}$
  - O Other, please specify.

b. Please explain the nature and scope of edits, reviews and/or provider education reviews performed.

If "No", do you plan on implementing RetroDUR activity and/or provider education in regard to beneficiaries with a diagnosis history of OUD or opioid poisoning in the future?

O Yes, when do you plan on implementing?

O No, please explain.

13. Does your MCO program develop and provide prescribers with pain management or opioid prescribing guidelines?

O Yes O No

If "Yes", please check **all** that apply.

- O Your prescribers are referred to the Center for Disease Control (CDC) Guideline for Prescribing Opioids for Chronic Pain
- O Other guidelines, please identify.

O No guidelines are offered, please explain.

14. Do you have a drug utilization management strategy that supports abuse deterrent opioid use to prevent opioid misuse and abuse (i.e. presence of an abuse deterrent opioid with preferred status on your preferred drug list)?

O Yes, please explain.

O No

#### D. MORPHINE MILLIGRAM EQUIVALENT (MME) DAILY DOSE

1. Have you set recommended maximum MME daily dose measures?

O Yes O No

If "Yes", please continue.

- a. What is your maximum MME daily dose limit in milligrams?
  - O Less than 50 MME, please specify: \_\_\_\_\_ mg per day
  - O 50 MME
  - O 70 MME
  - O 80 MME
  - O 90 MME
  - O 100 MME
  - O 120 MME
  - O 200 MME
  - O Greater than 200 MME, please specify. \_\_\_\_\_ mg per day
  - O Other, please specify. \_\_\_\_\_ mg per day
- b. Please explain nature and scope of dose limit (i.e. who does the edit apply to? Does the limit apply to **all** opioids? Are you in the process of tapering patients to achieve this limit)?

If "No," please explain the measure or program you utilize.

2.	Do you have an edit in your POS system that alerts the pharmacy provider that the MME daily dose prescribed has been exceeded?
	O Yes O No
	If "Yes", do you require PA if the MME limit is exceeded? O Yes O No
3.	Do you have automated retrospective claim reviews to monitor total daily dose (MME) of opioid prescriptions dispensed?
	O Yes, please explain.
	O No, please explain.

### E. OPIOID USE DISORDER (OUD) TREATMENT

1. Do you have utilization controls (i.e. PDL, PA, QL) to either monitor or manage the prescribing of Medication Assisted Treatment (MAT) drugs for OUD?

O Yes, please explain.

С	No
	es your MCO set total mg per day limits on the use of buprenorphine and prenorphine/naloxone combination drugs?
_	Yes No
	If "Yes", please specify the total mg/day.
	O 12 mg
	O 16 mg

- 3. What are your limitations on the allowable length of this treatment?
  - O No limit

2.

- O 3 months or less
- O 6 months
- $O_{12}$  months
- O 24 months
- O Other, please explain.

4. Do you require that the maximum mg per day allowable be reduced after a set period of time?

O Yes O No

If "Yes", please continue.

- a. What is your reduced (maintenance) dosage?
  - O 8 mg
  - O 12 mg
  - O 16 mg
  - O Other, please explain.

- b. What are your limitations on the allowable length of the reduced dosage treatment?
  - O 6 months
  - $O_{12}$  months
  - O No limit
  - O Other, please explain.

5. Do you have at least one buprenorphine/naloxone combination product available without prior authorization?

O Yes O No

- 6. Do you currently have edits in place to monitor opioids being used concurrently with any buprenorphine drug or any form of MAT?
  - O YesO NoO Other, please explain.

If "Yes", can the POS pharmacist override the edit?

- O Yes O No
- 7. Is there at least one formulation of naltrexone for OUD available without PA?
  - O Yes O No
- 8. Do you have at least one naloxone opioid overdose product available without PA?
  - O Yes O No
- 9. Do you retrospectively monitor and manage appropriate use of naloxone to persons at risk of overdose?
  - O Yes O No

Please explain above response.

10. Does your MCO allow pharmacists to dispense naloxone prescribed independently or by collaborative practice agreements, standing orders, or other predetermined protocols?

O Yes, please explain.

O No

## F. OUTPATIENT TREATMENT PROGRAMS (OTP)

1. Does your MCO cover OTPs that provide both services, Behavioral Health (BH) and MAT through OTPs?

O Yes O No, please explain.

If "Yes", is a referral needed for OUD treatment through OTPs?

O Yes, please explain.

O No, please explain.

Doe OUI	s your MCO cover buprenorphine or buprenorphine/naloxone for diagnose D as part of a comprehensive MAT treatment plan through OTPs?
	Yes
0	No, please explain.
	s your MCO cover naltrexone for diagnoses of OUD as part of a comprehe T treatment plan?
0	Yes
0	No, please explain.
	OUI O O Doe MA

## G. ANTIPSYCHOTICS /STIMULANTS

## ANTIPSYCHOTICS

1. Do you currently have restrictions in place to limit the quantity of antipsychotics?

O Yes

O No

Enter restrictions other than quantity limits below, or N/A.

2. Do you have a documented program in place to either manage or monitor the appropriate use of antipsychotic drugs in children?

O Yes O No

If "No", skip to question 2.d.

If "Yes", please continue.

- a. Do you either manage or monitor?
  - O Only children in foster care
  - O All children
  - O Other, please explain.

- b. Do you have edits in place to monitor (check **all** that apply)?
  - O Child's Age
  - O Dosage
  - $\mathsf{O}$  Indication
  - O Polypharmacy
  - O Other, please explain.

c.	Please briefly explain the specifics of your antipsychotic monitoring
	program(s).

\_\_\_\_\_

If "No", please continue.

- d. Do you plan on implementing a program in the future?
  - O Yes, please specify when.
  - O No, please explain why you will not be implementing a program to monitor the appropriate use of antipsychotic drugs in children.

\_\_\_\_\_

#### STIMULANTS

3. Do you currently have restrictions in place to limit the quantity of stimulants?

O Yes O No

- 4. Do you have a documented program in place to either manage or monitor the appropriate use of stimulant drugs in children?
  - O Yes O No

If "No", skip to question 4.d.

If "Yes", please continue.

- a. Do you either manage or monitor?
  - O Only children in foster care
  - O All children
  - O Other, please explain.

- b. Do you have edits in place to monitor (check **all** that apply)?
  - O Child's Age
  - O Dosage
  - O Indication
  - O Polypharmacy
  - O Other, please explain.

c. Please briefly explain the specifics of your documented stimulant monitoring program(s).

If "No", please continue.

- d. If you do not have a documented stimulant monitoring program in place, do you plan on implementing a program in the future?
  - O Yes, please specify when.
  - O No, please explain why you will not be implementing a program to monitor the appropriate use of stimulant drugs in children.

#### VIII. INNOVATIVE PRACTICES


1. Does your MCO participate in any demonstrations or have any waivers to allow importation of certain drugs from Canada or other countries that are versions of FDA-approved drugs for dispensing to Medicaid Beneficiaries?

O Yes, please explain.

O No

#### 2. Summary 4: Innovative Practices

Have you developed any innovative practices during the past year (i.e. Substance Use Disorder, Hepatitis C, Cystic Fibrosis, MMEs, Value Based Purchasing)? Please describe in detailed narrative below any innovative practices that you believe have improved the administration of your DUR program, the appropriateness of prescription drug use and/or have helped to control costs (i.e. disease management, academic detailing, automated prior authorizations, continuing education programs).



#### IX. EXECUTIVE SUMMARY

#### **Summary 5: Executive Summary**

Please include a general overview and summary of program highlights from FFY 2019 as well as objectives, tools and outcomes of initiatives accomplished, as well as goals for FFY 2020. Include a summary of program oversight and initiatives.

# **APPENDIX A: MCO PROGRAM TYPES**

#### **DEFINITIONS OF MANAGED CARE PROGRAM TYPES**

A managed care program is defined by the set of benefits covered and the type of participating managed care plans (e.g., MCOs, PHPs, PACE, etc.) or providers (e.g., PCCM providers).

Managed Care Program TypeDefinition	
	Comprehensive Managed Care Organization: A program in which the State contracts with managed care plans to cover all acute and primary medical services; some also cover behavioral health, dental, transportation and long term care. Entities that qualify as MCOs include Health Maintenance Organizations (HMOs) and Health Insuring Organizations (HIOs in California).
	If the comprehensive MCO also covers long-term services and supports, the program type should be Comprehensive MCO + MLTSS.
Comprehensive MCO	When certain benefits, such as behavioral health, dental, or transportation, are carved out of the comprehensive MCO program and covered through a limited benefit program (i.e. a Prepaid Inpatient Health Plan or Prepaid Ambulatory Health Plan), enrollees in such limited benefit plans should be reported in separate programs of the appropriate type (e.g., BHO (PIHP and/or PAHP), Dental PAHP, or Non-Emergency Medical Transportation, or an MLTSS-only program when only LTSS and no other services are covered.
	Individual beneficiaries can be enrolled in only one comprehensive MCO program (either a comprehensive MCO or a comprehensive MCO+MLTSS) as of the July 1 point in time.
Comprehensive MCO + MLTSS	Comprehensive Managed Care Organization + Managed Long-Term Services and Supports: A program in which plans cover comprehensive acute and outpatient benefits as defined above, where the same plan also covers long- term services and supports (LTSS).
	Individual beneficiaries can be enrolled in only one comprehensive MCO program (either a comprehensive MCO or a comprehensive MCO+MLTSS).
BHO Only (PIHP and/or PAHP)	Behavior Health Organizations Only (Prepaid Inpatient Health Plan and/or Prepaid Ambulatory Health Plan): A program specializing in behavioral health (mental health and/or substance use disorder) services. Services are covered on a prepaid basis.

#### FFY 2020 MANAGED CARE ORGANIZATION DRUG UTILIZATION REVIEW ANNUAL SURVEY

Managed Care Program Type	Definition
Dental only (PAHP)	A Prepaid Ambulatory Health Program (PAHP) that only provides dental services.
MLTSS Only	Managed Long Term Services and Supports Only: A program only covering long term services and supports.
Other PHP	Other Prepaid Health Plan: A program covering a limited set of services through PIHPs or PAHPs not otherwise included above. Examples include disease management and pharmacy benefits.
PACE	Programs of All-Inclusive Care for the Elderly: A program that provides prepaid, capitated comprehensive medical and social services in an adult day health center, supplemented by in-home and referral services according to a participant's needs. To qualify, individuals must: (1) be 55 years of age or older, (2) meet a nursing home level of care, and (3) live in a PACE organization service area.
PCCM	Primary Care Case Management: A managed care arrangement in which primary care providers contract with the state to provide a core set of case management services to the enrollees assigned to them and to serve as the enrollees' home for medical care, in exchange for a monthly case management fee. All other services are reimbursed on a FFS basis. Primary Care Providers (PCPs) can include primary care physicians, clinics, group practices and nurse practitioners, among others. In general, we would only expect case management and physician services to be covered under capitation for PCCM programs.
PCCM entity	Primary Care Case Management entity: In addition to providing primary care case management services for the State, a PCCM entity is an organization that provides any of the following functions: (1) Provision of intensive telephonic or face-to-face case management, including operation of a nurse triage advice line; (2) Development of enrollee care plans; (3) Execution of contracts with and/or oversight responsibilities for the activities of FFS providers in the FFS program; (4) Provision of payments to FFS providers on behalf of the State; (5) Provision of enrollee outreach and education activities; (6) Operation of a customer service call center; (7) Review of provider claims, utilization and practice patterns to conduct provider profiling and/or practice improvement; (8) Implementation of quality improvement activities including administering enrollee satisfaction surveys or collecting data necessary for performance measurement of providers; (9) Coordination with behavioral health systems/providers; and/or (10) Coordination with long-term services and supports systems/ providers.

Managed Care Program Type	Definition
Non-Emergency Medical Transportation (NEMT)	A program that covers transportation to and from medically necessary health care services in which these services are paid for on a per capita basis (the state pays the transportation broker based on the number of people served, not the amount of service or trips that each individual receives). Do not report transportation programs in which individual trips are reimbursed on a FFS basis.

## MANAGED CARE PLAN CROSSWALK

The table below provides a crosswalk for plan types to program types.

Managed Care Plan Type	Managed Care Program Type
Comprehensive MCO	<ul> <li>Comprehensive MCO</li> <li>Comprehensive MCO         <ul> <li>+MLTSS (if benefits include LTSS)</li> </ul> </li> </ul>
Traditional PCCM Provider	• PCCM
Enhanced PCCM Provider	• PCCM
HIO	Comprehensive MCO
Medical-only PIHP (risk or non-risk/non- comprehensive/with inpatient hospital or institutional services)	• Other PHP
Medical-only PAHP (risk or non-risk/non- comprehensive/no inpatient hospital or institutional services)	• Other PHP
Long Term Care (LTC) PIHP	MLTSS Only
Mental Health (MH) PIHP	• BHO (PIHP and/or PAHP)
Mental Health (MH) PAHP	• BHO (PIHP and/or PAHP)
Substance Use Disorders (SUD) PIHP	• BHO (PIHP and/or PAHP)
Substance Use Disorders (SUD) PAHP	• BHO (PIHP and/or PAHP)
Mental Health (MH) and Substance Use Disorders (SUD) PIHP	• BHO (PIHP and/or PAHP)
Mental Health (MH) and Substance Use Disorders (SUD) PAHP	• BHO (PIHP and/or PAHP)
Dental PAHP	• Dental
Transportation PAHP	• NEMT
Disease Management PAHP	• Other PHP
PACE	• PACE
Pharmacy PAHP	• Other PHP
	Comprehensive MCO
Accountable Care Organization	• Other PHP
	• PCCM
Health/Medical Home	• PCCM

#### FFY 2020 MANAGED CARE ORGANIZATION DRUG UTILIZATION REVIEW ANNUAL SURVEY

Integrated Care For Dual Eligibles	<ul> <li>Comprehensive MCO + MLTSS,</li> <li>MLTSS Only (if benefits cover LTSS)</li> </ul>
Unknown – it is not yet known how PCCM entities will be reported in T-MSIS.	• PCCM entity

## **APPENDIX B: DRUG NAMES**

Abacavir/Dolutegravir/Lamivudi Accolate Accupril Acetaminophen Acitretin Acyclovir Adalimumab Aflibercept Albuterol Albuterol Sulfate/Ipratropium Bromide Alendronate Sodium Allopurinol Alprazolam Ambrisentan Amiodarone Hydrochloride Amitriptyline Amlodipine Amlodipine Besylate/Benazepril Hydrochloride Amoxicillin Amoxicillin/Potassium Clav Amoxicillin: Clavulanate Potassium Amphetamine Androgens Antihemophilic Factors Anti-Inhibitor Coagulant Comp. Apixaban Apraclonidine Argatroban Aricept Aripiprazole Asenapine Maleate Aspirin Atazanavir Atenolol Atomoxetine Atorvastatin Azithromycin Bacitracin/Neomycin/ Polymyxin B Baclofen Beclomethasone Benazepril Hydrochloride Benzonatate Benztropine Mesylate

Bevacizumab Brexipiprazole Brimonidine Tartrate Budesonide Budesonide/ Formoterol Buprenorphine Buprenorphine Hcl/Naloxone Hcl **Bupropion** Buspirone Hydrochloride Canagliflozin Carbamazepine Carbidopa/ Levodopa Carisoprodol Carvedilol Celecoxib Cephalexin Cetirizine Chlorthalidone Cholecalciferol Cinacalcet Hcl Ciprofloxacin Citalopram Clindamycin Clobazam **Clobetasol Propionate** Clonazepam Clonidine **Clopidogrel Bisulfate Coagulation Factors** Contraceptives Corticotropin Cyanocobalamin Cyclobenzaprine Cyclosporine Darbepoetin Alfa In Polysorbat Darunavir Ethanolate Darunavir/Cobicistat Deferasirox Deferoxamine Deserasirox Desogestrel/ Ethinyl Estradiol Dexlansoprazole

Dexmethylphenidate Dextroamphetamine/Amphetamine Diazepam Diclofenac Dicyclomine Hydrochloride Digoxin Diltiazem Hydrochloride **Dimethyl Fumarate** Diphenhydramine **Divalproex Sodium** Docusate Dolutegravir Donepezil Dornase Dorzolamide Hydrochloride/Timolol Maleate Doxazosin Mesylate Doxycycline Drospirenone/ Ethinyl Estradiol Duloxetine Eculizumab Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Elbasvir/Grazoprevir Elviteg/Cob/Emtri/Tenofo Disop Elvitegravir/Cobicistat/Emtricitabine/Tenof ovir Alafenamide Emtricita/Rilpivirine/Tenof Df Emtricitabine/Tenofovir Alafenamide **Enalapril Maleate Enoxaparin Sodium** Entecavir **Epoetin** Alfa Ergocalciferol Escitalopram Esomeprazole Estradiol Etanercept Estrogens **Everolimus** Exenatide Ezetimibe Famotidine Fenofibrate

Fentanyl Ferrous Sulfate Filgrastim Finasteride Fingolimod Fluconazole Fluoxetine Fluticasone Fluticasone Propionate/ Salmeterol Xinafoate Fluticasone/Salmeterol Fluticasone/Vilanterol Folic Acid Furosemide Gabapentin Gemfibrozil Glatiramer Glimepiride Glipizide Glyburide Guanfacine Guanfacine Hcl Er Haloperidol Hctz Heparin Hydralazine Hydrochloride Hydrochlorothiazide Hydrochlorothiazide/ Lisinopril Hydrochlorothiazide/ Losartan Potassium Hydrochlorothiazide/ Triamterene Hydrochlorothiazide/Valsartan Hydrocodone Hydrocodone /Apap Hydrocortisone Hydromorphone Hydroxychloroquine Sulfate Hydroxyprogesterone Hydroxyzine Ibuprofen Imatinib Mesylate **Immune Globulins** Infliximab **Insulin Aspart** Insulin Detemir

Insulin Glargine Insulin Human Insulin Lispro Ipratropium Ipratropium/Albuterol Irbesartan Isosorbide Mononitrate Ketoconazole Lacosamide Lamotrigine Lansoprazole Latanoprost Ledipasvir/Sofosbuvir Lenalidomide Leuprolide Acetate Levalbuterol Hcl Levetiracetam Levocetirizine Dihydrochloride Levofloxacin Levothyroxine Lidocaine Linaclotide Linagliptin Lipase/Protease/Amylase Liraglutide Lisdexamfetamine Lisinopril Lithium Loratadine Lorazepam Losartan Lovastatin Lumacaftor/Vacaftor Lurasidone Magnesium Meclizine Hydrochloride Meloxicam Memantine Hydrochloride Metformin Metformin Hydrochloride/ Sitagliptin Phosphate Methocarbamol Methotrexate Methylcellulose (4000 Mpa.S) Methylphenidate Methylprednisolone

Metoprolol Metronidazole Mirtazapine Mometasone Mometasone/Formoterol Montelukast Morphine Mupirocin Naloxone Naltrexone Naltrexone Microspheres Naproxen Natalizumab Nebivolol Hydrochloride Nicotine Patch Nifedipine Nitrofurantoin Nitroglycerin Nivolumab Nortriptyline Hydrochloride Olanzapine Olmesartan Medoxomil Olopatadine Omalizumab **Omega-3-Acid Ethyl Esters** Omeprazole Ondansetron Oseltamivir Oxybutynin Oxycodone Oxycodone/Apap Palbociclib Paliperidone Palivizumab Pantoprazole Sodium Paroxetine Pegfilgrastim Pioglitazone Polyethylene Glycol 3350 Potassium Pravastatin Sodium Prednisolone Prednisone Pregabalin Progesterone

Promethazine Promethazine Hydrochloride Propranolol Quetiapine **Raltegravir Potassium** Ramipril Ranitidine Ranitidine Hcl Retinoids Rifaximin Risperidone **Risperidone Microspheres** Ritonavir Rituximab Rivaroxaban Ropinirole Hydrochloride Rosuvastatin Rufinamide Sertraline Sertraline Hydrochloride Sevelamer Hcl Simvastatin Sitagliptin Sitagliptin Phos/Metformin Hcl Sodium Chloride Sofosbuvir/Velpatasvir Solifenacin Succinate Somatropin Spironolactone Sulfamethoxazole/ Trimethoprim Sumatriptan Tacrolimus Tamsulosin Hydrochloride Temazepam Tenofovir Disoproxil Fumarate Terazosin Teriflunomide Testosterone Thyroid Timolol Tiotropium Tizanidine Topiramate Tramadol Trastuzumab

Trazodone Treprostinil Sodium Triamcinolone Ustekinumab Valacyclovir Valsartan Varenicline Vedolizumab Venlafaxine Verapamil Vitamins Warfarin Zolpidem

# **APPENDIX C: DRUG CLASSES**

Drug Class	Description
Analgesics	Drugs that relieve pain. There are two main types:
	non-narcotic analgesics for mild pain, and
	narcotic analgesics for severe pain.
Antacids	Drugs that relieve indigestion and heartburn by
	neutralizing stomach acid.
Antianxiety Drugs	Drugs that suppress anxiety and relax muscles
	(sometimes called anxiolytics, sedatives, or minor
	tranquilizers).
Antiarrhythmics	Drugs used to control irregularities of heartbeat.
Antibacterials	Drugs used to treat infections.
Antibiotics	Drugs made from naturally occurring and
	synthetic substances that combat bacterial
	infection. Some antibiotics are effective only
	against limited types of bacteria. Others, known as
	broad spectrum antibiotics, are effective against a
	wide range of bacteria.
Anticoagulants and Thrombolytics	Anticoagulants prevent blood from clotting.
	Thrombolytics help dissolve and disperse blood
	clots and may be prescribed for patients with
	recent arterial or venous thrombosis.
Anticonvulsants	Drugs that prevent epileptic seizures.
Antidepressants	There are three main groups of mood-lifting
	antidepressants: tricyclics, monoamine oxidase
	inhibitors, and selective serotonin reuptake
	inhibitors (SSRIs).
Antidiarrheals	Drugs used for the relief of diarrhea. Two main
	types of antidiarrheal preparations are simple
	adsorbent substances and drugs that slow down the contractions of the bowel muscles so that the
Antiemetics	contents are propelled more slowly. Drugs used to treat nausea and vomiting.
	Drugs used to treat fungal infections, the most
Antifungals	common of which affect the hair, skin, nails, or
	mucous membranes.
Antihistamines	Drugs used primarily to counteract the effects of
Antimistammes	histamine, one of the chemicals involved in
	allergic reactions.
Antihypertensives	Drugs that lower blood pressure. The types of
Antiny per tensives	antihypertensives currently marketed include
	diuretics, beta-blockers, calcium channel blocker,
	ACE (angiotensin- converting enzyme) inhibitors,
	centrally acting antihypertensives and
	sympatholytics.
Anti-Inflammatories	Drugs used to reduce inflammation - the redness,
	heat, swelling, and increased blood flow found in

FFY 2020

Drug Class	Description
	infections and in many chronic noninfective
	diseases such as rheumatoid arthritis and gout.
Antineoplastics	Drugs used to treat cancer.
Antipsychotics	Drugs used to treat symptoms of severe
	psychiatric disorders. These drugs are sometimes
	called major tranquilizers.
Antipyretics	Drugs that reduce fever.
Antivirals	Drugs used to treat viral infections or to provide
	temporary protection against infections such as
	influenza.
Barbiturates	See "sleeping drugs."
Beta-Blockers	Beta-adrenergic blocking agents, or beta-blockers
	for short, reduce the oxygen needs of the heart by
	reducing heartbeat rate.
Bronchodilators	Drugs that open up the bronchial tubes within the
	lungs when the tubes have become narrowed by
	muscle spasm. Bronchodilators ease breathing in
	diseases such as asthma.
Cold Cures	Although there is no drug that can cure a cold, the
	aches, pains, and fever that accompany a cold can
	be relieved by aspirin or acetaminophen often
	accompanied by a decongestant, antihistamine,
	and sometimes caffeine.
Corticosteroids	
Corticosteroius	These hormonal preparations are used primarily as anti-inflammatories in arthritis or asthma or as
	immunosuppressives, but they are also useful for
	treating some malignancies or compensating for a
	deficiency of natural hormones in disorders such
	as Addison's disease.
Cough Suppressants	Simple cough medicines, which contain
	substances such as honey, glycerine, or menthol,
	soothe throat irritation but do not actually
	suppress coughing. They are most soothing when
	taken as lozenges and dissolved in the mouth. As
	liquids they are probably swallowed too quickly
	to be effective. A few drugs are actually cough
	suppressants. There are two groups of cough
	suppressants: those that alter the consistency or
	production of phlegm such as mucolytics and
	expectorants; and those that suppress the coughing
	reflex such as codeine (narcotic cough
	suppressants), antihistamines, dextromethorphan
	and isoproterenol (non-narcotic cough
	suppressants).
Cytotoxics	Drugs that kill or damage cells. Cytotoxics are
	used as antineoplastics (drugs used to treat cancer)
	and also as immunosuppressives.
Decongestants	Drugs that reduce swelling of the mucous
0	membranes that line the nose by constricting

Drug Class	Description
Diuretics	Drugs that increase the quantity of urine produced
	by the kidneys and passed out of the body, thus
	ridding the body of excess fluid. Diuretics reduce
	water logging of the tissues caused by fluid
	retention in disorders of the heart, kidneys, and
	liver. They are useful in treating mild cases of
	high blood pressure.
Expectorant	A drug that stimulates the flow of saliva and
	promotes coughing to eliminate phlegm from the
	respiratory tract.
Hormones	Chemicals produced naturally by the endocrine
	glands (thyroid, adrenal, ovary, testis, pancreas,
	parathyroid). In some disorders, for example,
	diabetes mellitus, in which too little of a particular
	hormone is produced, synthetic equivalents or
	natural hormone extracts are prescribed to restore
	the deficiency. Such treatment is known as
	hormone replacement therapy.
Hypoglycemics (Oral)	Drugs that lower the level of glucose in the blood.
	Oral hypoglycemic drugs are used in diabetes
	mellitus if it cannot be controlled by diet alone,
	but does require treatment with injections of
	insulin.
Immunosuppressives	Drugs that prevent or reduce the body's normal
	reaction to invasion by disease or by foreign
	tissues. Immunosuppressives are used to treat
	autoimmune diseases (in which the body's
	defenses work abnormally and attack its own
	tissues) and to help prevent rejection of organ
	transplants.
Laxatives	Drugs that increase the frequency and ease of
	bowel movements, either by stimulating the bowel
	wall (stimulant laxative), by increasing the bulk of
	bowel contents (bulk laxative), or by lubricating
	them (stool-softeners, or bowel movement-
	softeners). Laxatives may be taken by mouth or
	directly into the lower bowel as suppositories or
	enemas. If laxatives are taken regularly, the
	bowels may ultimately become unable to work
	properly without them.
Muscle Relaxants	Drugs that relieve muscle spasm in disorders such
	as backache. Antianxiety drugs (minor
	tranquilizers) that also have a muscle-relaxant
	action are used most commonly.
Sedatives	Same as Antianxiety drugs.
Sex Hormones (Female)	There are two groups of these hormones
sea avenuer (i chime)	(estrogens and progesterone), which are
	responsible for development of female secondary
	sexual characteristics. Small quantities are also
	produced in males. As drugs, female sex
	hormones are used to treat menstrual and
	normones are used to treat menstrual and

Drug Class	Description
<u>v</u>	menopausal disorders and are also used as oral
	contraceptives. Estrogens may be used to treat
	cancer of the breast or prostate, progestins
	(synthetic progesterone to treat endometriosis).
Sex Hormones (Male)	Androgenic hormones, of which the most
	powerful is testosterone, are responsible for
	development of male secondary sexual
	characteristics. Small quantities are also produced
	in females. As drugs, male sex hormones are
	given to compensate for hormonal deficiency in
	hypopituitarism or disorders of the testes. They
	may be used to treat breast cancer in women, but
	either synthetic derivatives called anabolic
	steroids, which have less marked side- effects, or
	specific anti-estrogens are often preferred.
	Anabolic steroids also have a "body building"
	effect that has led to their (usually nonsanctioned)
	use in competitive sports, for both men and
	women.
Sleeping Drugs	The two main groups of drugs that are used to
	induce sleep are benzodiazepines and barbiturates.
	All such drugs have a sedative effect in low doses
	and are effective sleeping medications in higher
	doses. Benzodiazepines drugs are used more
	widely than barbiturates because they are safer,
	the side-effects are less marked, and there is less
	risk of eventual physical dependence.
Tranquilizer	This is a term commonly used to describe any
	drug that has a calming or sedative effect.
	However, the drugs that are sometimes called
	minor tranquilizers should be called antianxiety
	drugs, and the drugs that are sometimes called
	major tranquilizers should be called
	antipsychotics.
Vitamins	Chemicals essential in small quantities for good
	health. Some vitamins are not manufactured by
	the body, but adequate quantities are present in a
	normal diet. People whose diets are inadequate or
	who have digestive tract or liver disorders may
	need to take supplementary vitamins.
Other	Please specify.

# **APPENDIX D: DENIAL CODES**

ACCUMULATION REFILL TOO SOON
AGE
BRAND REQUEST
CLAIM REQUIRES AN APPROVED TREATMENT
AUTHORIZATION REQUEST (TAR)
CLAIM SUBMITTED DOES NOT MATCH PA
COMPLIANCE MONITORING/EARLY OR LATE REFILL
CUMULATIVE EARLY REFILL
DAILY DOSE EXCEEDED
DAYS SUPPLY
DRUG COVERED BY MEDICARE PART D
DRUG LIST INITIATIVE THRESHOLD
DRUG-DISEASEREPORTED PRECAUTION
DRUG-DRUG INTERACTION
DUPLICATE CLAIM
DUR REJECT ERROR
EARLY REFILL: OVERUSE PRECAUTION
ELIGIBILITY
EXCEEDS ALLOWABLE PLAN DAYS SUPPLY
FILLED AFTER COVERAGE TERMINATED
HIGH DOSE ALERT
M/I DAYS SUPPLY
M/I DIAGNOSIS CODE
M/I OTHER COVERAGE CODE
M/I PRESCRIBER
MD MUST CALL FOR A PRIOR AUTHORIZATION
MEMBER ENROLLED IN MANAGED CARE
MEMBERS BENEFITS PACKAGE DOES NOT INCLUDE
THIS MEDICATION
NDC NOT CONSISTENT WITH ANY BILLED
DIAGNOSIS
NDC NOT COVERED
NDC VS DIAGNOSIS RESTRICTION
NO REBATE
NON-COVERED AND NON-REBATE PRODUCTS
NON-MATCHED PRESCRIBER ID

FFY 2020 MANAGED CARE ORGANIZATION DRUG UTILIZATION REVIEW ANNUAL SURVEY

NON-PREFERRED DRUG
OVER UTILIZATION PRECAUTION
PATIENT IS NOT COVERED
PDL
PHARMACY MAINTENANCE SUPPLY REQUIRED FOR
DRUG
PLAN LIMITATIONS EXCEEDED
PRESCRIBER IS NOT COVERED
PRIOR AUTHORIZATION REQUIRED
PRODUCT/SERVICE NOT COVERED – PLAN/BENEFIT
EXCLUSION
PRODUR ALERT
PROVIDER NOT ENROLLED IN BENEFIT PLAN
BILL MEDICARE
QUANTITY DISPENSED EXCEEDS MAXIMUM
ALLOWED
REFILL EXCEEDS MAX. ALLOWABLE REFILLS
REFILL TOO SOON
REPORTED DISEASE
SERVICE NOT COVERED
SUBMIT BILL TO OTHER PROCESSOR OR PRIMARY
PAYOR
TAMPER PROOF PAD REQD
THERAPEUTIC DUPLICATION
UNDER UTILIZATION PRECAUTION